Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | CD38 | P28907 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12513462 | 1.00 | PRKAA2 (0.47) | PRKAA2HSD11B1CD38CNR2GRM4 | |
| SCHEMBL19701368 | 0.83 | SMYD3 (0.50) | PRKAA2HSD11B1SMYD3 | |
| SCHEMBL21489946 | 0.83 | SMYD3 (0.50) | PRKAA2HSD11B1SMYD3 | |
| SCHEMBL26412830 | 0.83 | HSD11B1 (0.63) | PRKAA2HSD11B1CD38CNR2PARP1 | |
| SCHEMBL31514789 | 0.81 | CNR2 (0.59) | PRKAA2HSD11B1CNR2GRM4 | |
| SCHEMBL23575973 | 0.79 | SMYD3 (0.65) | SMYD3 | |
| SCHEMBL19710214 | 0.79 | SMYD3 (0.65) | SMYD3 | |
| SCHEMBL22722015 | 0.78 | SMYD3 (0.64) | SMYD3 | |
| SCHEMBL12436733 | 0.78 | SMYD3 (0.64) | SMYD3 | |
| SCHEMBL20103216 | 0.73 | HTR1F (0.45) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | PRKAA2 4122/4885HSD11B1 1352/4885CD38 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.